Compare Diamondback Energy Inc (FANG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Recursion Pharmaceuticals Inc — how do they compare? Diamondback Energy Inc trades at $190.8 (market cap $53.38B), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.75B). The key difference: Diamondback Energy Inc is far larger — about 30.5× Recursion Pharmaceuticals Inc's market cap, and Diamondback Energy Inc pays a 2.32% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| FANG | RXRX | |
|---|---|---|
Market Cap | $53.38B | $1.75B |
Sector | Energy | Health |
52-Week High | $213.69 | $6.79 |
52-Week Low | $134.53 | $2.84 |
Enterprise Value | $67.11B | $1.17B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $191.28, up 0.31% on the day, with a bullish technical signal and strong analyst support. Recent earnings show mixed results, beating estimates in Q1 2026 but missing in Q4 2025, while revenue growth remains robust. The company maintains solid cash flow from operations and a manageable debt-to-asset ratio of 22.26% as of 2025. A dividend of $1.10 was recently declared, with the next earnings report scheduled for August 3, 2026.
FANG presents a favorable outlook with a consensus price target of $234.50, implying 22.6% upside, supported by 90% buy ratings from analysts. Risks include volatile oil prices, geopolitical factors affecting energy markets, and declining net income margins. The stock's high P/E ratio of 193.63 warrants caution, but strong operational cash flow and institutional bullishness provide a solid foundation for growth-oriented investors.
Recursion Pharmaceuticals (RXRX) trades at $3.175, down 4.94% on the day, reflecting ongoing investor concerns about profitability. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal significant losses with a net income margin of -851.51% despite recent earnings beats. Analyst consensus is mixed with 40% buy ratings but a $7.83 price target suggesting substantial upside potential from current levels.
The outlook remains speculative given the company's heavy losses and cash burn, though AI-driven drug discovery platform and recent clinical progress offer long-term potential. Key risks include prolonged unprofitability, intense biotech competition, and dependence on successful drug development. The stock presents high-risk/high-reward characteristics suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
